Use of Combined Chemotherapy with Etoposide and Methotrexate, both Associated to Lipid Nanoemulsions for Atherosclerosis Treatment in Cholesterol-fed Rabbits
Carregando...
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2015
Editora
SPRINGER
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CARDIOVASCULAR DRUGS AND THERAPY, v.29, n.1, p.15-22, 2015
Resumo
Treatment of atherosclerotic rabbits with intravenous methotrexate or etoposide carried in lipid nanoemulsions (LDE) markedly reduced the lesions in the aorta. Here, the combined treatment with LDE-methotrexate and LDE-etoposide was investigated aiming to increase the anti-atherosclerosis effect. Thirty-six male rabbits received a diet with 1 % cholesterol for 2 months. After the first month, the animals received 4 weekly intravenous injections of LDE-methotrexate (4 mg/kg dose), LDE-etoposide (6 mg/kg), or a combination of those two drugs, while the control animals were injected with LDE (n = 9 for each group). LDE-methotrexate+LDE-etoposide reduced aortic lesion areas by 95 % compared with controls and the intima-media ratio was reduced five-fold, whereas LDE-methotrexate reduced the lesions by 81 % and LDE-etoposide by 83 %. Compared to controls, the positive area of macrophages and MMP-9 in the arterial intima was significantly reduced in all treated groups (p < 0.001), but the MMP9 reduction was greater with the combined chemotherapy than the reduction achieved by the isolated treatments. Presence of CD3 positive cells was equal in controls and LDE-methotrexate+LDE-etoposide treated animals. However, FOXP3 positive T lymphocytes in the intima were increased in the LDE-methotrexate+LDE-etoposide rabbits. Weight, food intake evolution and the hematologic parameters suggested that the treatment had very low toxicity. Compared to the single treatments with LDE-methotrexate and LDE-etoposide, the combined treatment was more effective in reducing the atherosclerotic lesions. Because the toxicity of the novel drug-target combined scheme was low, those results favor the possibility of future clinical studies in patients with cardiovascular disease.
Palavras-chave
Atherosclerosis treatment, Nanoparticles, Cholesterol, Methotrexate, Etoposide, Solid lipid particles
Referências
- BONNEY RJ, 1975, CANCER RES, V35, P1950
- Bulgarelli A, 2013, CARDIOVASC DRUG THER, V27, P531, DOI 10.1007/s10557-013-6488-3
- Bulgarelli A, 2012, J CARDIOVASC PHARM, V59, P308, DOI 10.1097/FJC.0b013e318241c385
- Charo IF, 2011, NAT REV DRUG DISCOV, V10, P365, DOI 10.1038/nrd3444
- DELALLERAMOYA M, 1992, ARTERIOSCLER THROMB, V12, P1363
- Dias MLN, 2007, CANCER CHEMOTH PHARM, V59, P105, DOI 10.1007/s00280-006-0252-3
- Engel R, 2004, EXP CELL RES, V295, P421, DOI 10.1016/j.yexcr.2004.01.012
- Esparza L, 2012, INTERACT CARDIOV TH, V15, P340, DOI 10.1093/icvts/ivs123
- Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/hh0302.105345
- GINSBURG GS, 1982, J BIOL CHEM, V257, P8216
- Hall TC, 1996, EUR J CANCER, V2, P135
- JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131
- MARANHAO RC, 1993, LIPIDS, V28, P691, DOI 10.1007/BF02535988
- Maranhao RC, 2008, ATHEROSCLEROSIS, V197, P959, DOI 10.1016/j.atherosclerosis.2007.12.051
- Maranhao RC, 1997, LIPIDS, V32, P627, DOI 10.1007/s11745-997-0080-6
- Maranhao RC, 2002, CANCER CHEMOTH PHARM, V49, P487, DOI 10.1007/s00280-002-0437-3
- Ridker PM, 2009, J THROMB HAEMOST, V7, P332, DOI 10.1111/j.1538-7836.2009.03404.x
- ROSOWSKY A, 1984, J MED CHEM, V27, P605, DOI 10.1021/jm00371a009
- Ross R, 1999, NEW ENGL J MED, V340, P115
- Tavares ER, 2011, INT J NANOMED, V6, P2297, DOI 10.2147/IJN.S24048
- de Boer OJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000779
- Tian Henghe, 2007, Bull NYU Hosp Jt Dis, V65, P168
- Valduga CJ, 2003, J PHARM PHARMACOL, V55, P1615, DOI 10.1211/0022357022232
- Wessels JAM, 2008, RHEUMATOLOGY, V47, P249, DOI 10.1093/rheumatology/kem279